<?xml version='1.0' encoding='utf-8'?>
<document id="29245320"><sentence text="QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature."><entity charOffset="70-80" id="DDI-PubMed.29245320.s1.e0" text="fluoxetine" /><entity charOffset="85-95" id="DDI-PubMed.29245320.s1.e1" text="amiodarone" /><pair ddi="false" e1="DDI-PubMed.29245320.s1.e0" e2="DDI-PubMed.29245320.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29245320.s1.e0" e2="DDI-PubMed.29245320.s1.e1" /></sentence><sentence text="Drug-induced prolongation of the corrected QT interval (QTc) may lead to serious and potentially life-threatening ventricular tachyarrhythmia, such as torsades de pointes (Tdp), which is worthy of clinical attention" /><sentence text=" Here, we report 1 case of Tdp after a coadministration of fluoxetine and amiodarone"><entity charOffset="59-69" id="DDI-PubMed.29245320.s3.e0" text="fluoxetine" /><entity charOffset="74-84" id="DDI-PubMed.29245320.s3.e1" text="amiodarone" /><pair ddi="false" e1="DDI-PubMed.29245320.s3.e0" e2="DDI-PubMed.29245320.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29245320.s3.e0" e2="DDI-PubMed.29245320.s3.e1" /></sentence><sentence text="" /><sentence text="A 62-year-old Chinese male who placed with the implanted cardioverter-defibrillator (ICD) appeared the QTc prolongation and Tdp after the concurrent administration of fluoxetine and amiodarone"><entity charOffset="167-177" id="DDI-PubMed.29245320.s5.e0" text="fluoxetine" /><entity charOffset="182-192" id="DDI-PubMed.29245320.s5.e1" text="amiodarone" /><pair ddi="false" e1="DDI-PubMed.29245320.s5.e0" e2="DDI-PubMed.29245320.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29245320.s5.e0" e2="DDI-PubMed.29245320.s5.e1" /></sentence><sentence text="" /><sentence text="Torsades de pointes (Tdp)" /><sentence text="" /><sentence text="The patient was treated with magnesium and potassium immediately"><entity charOffset="29-38" id="DDI-PubMed.29245320.s9.e0" text="magnesium" /><entity charOffset="43-52" id="DDI-PubMed.29245320.s9.e1" text="potassium" /><pair ddi="false" e1="DDI-PubMed.29245320.s9.e0" e2="DDI-PubMed.29245320.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29245320.s9.e0" e2="DDI-PubMed.29245320.s9.e1" /></sentence><sentence text=" Her ICD-brady pacing mode was reprogrammed to 90â€Šbpm" /><sentence text=" Meanwhile, both of fluoxetine and amiodarone were discontinued"><entity charOffset="20-30" id="DDI-PubMed.29245320.s11.e0" text="fluoxetine" /><entity charOffset="35-45" id="DDI-PubMed.29245320.s11.e1" text="amiodarone" /><pair ddi="false" e1="DDI-PubMed.29245320.s11.e0" e2="DDI-PubMed.29245320.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29245320.s11.e0" e2="DDI-PubMed.29245320.s11.e1" /></sentence><sentence text="" /><sentence text="The further episodes of Tdp were prevented" /><sentence text=" After a few days, the QTc gradually decreased without clinically significant arrhythmias" /><sentence text="" /><sentence text="The present case demonstrates that a potential drug-drug interaction (DDI) may lead to a life-threatening drug adverse reaction (ADR) especially in special subjects" /><sentence text=" Therefore, clinicians should closely monitor the electrocardiogram (ECG) when QTc-prolonging agents are given to patients with cardiac abnormalities, and avoid combining 2 QTc-prolonging drugs" /><sentence text="" /></document>